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Abstract: Objective: Epidemiological studies link hyperlipidemia with increased risk for abdominal
aortic aneurysms (AAAs). However, the influence of lipid-lowering drugs statins on prevalence
and progression of clinical and experimental AAAs varies between reports, engendering contro-
versy on the association of hyperlipidemia with AAA disease. This study investigated the impact
of hypercholesterolemia on elastase-induced experimental AAAs in mice. Methods: Both sponta-
neous (targeted deletion of apolipoprotein E) and induced mouse hypercholesterolemia models
were employed. In male wild type (WT) C57BL/6J mice, hypercholesterolemia was induced via
intraperitoneal injection of an adeno-associated virus (AAV) encoding a gain-of-function proprotein
convertase subtilisin/kexin type 9 mutation (PCSK9) followed by the administration of a high-fat
diet (HFD) (PCSK9+HFD) for two weeks. As normocholesterolemic controls for PCSK9+HFD mice,
WT mice were infected with PCSK9 AAV and fed normal chow, or injected with phosphate-buffered
saline alone and fed HFD chow. AAAs were induced in all mice by intra-aortic infusion of porcine
pancreatic elastase and assessed by ultrasonography and histopathology. Results: In spontaneous
hyper- and normo-cholesterolemic male mice, the aortic diameter enlarged at a constant rate from day
3 through day 14 following elastase infusion. AAAs, defined as a more than 50% diameter increase
over baseline measurements, formed in all mice. AAA progression was more pronounced in male
mice, with or without spontaneous hyperlipidemia. The extent of elastin degradation and smooth
muscle cell depletion were similar in spontaneous hyper- (score 3.5 for elastin and 4.0 for smooth mus-
cle) and normo- (both scores 4.0) cholesterolemic male mice. Aortic mural macrophage accumulation
was also equivalent between the two groups. No differences were observed in aortic accumulation
of CD4+ or CD8+ T cells, B cells, or mural angiogenesis between male spontaneous hyper- and
normocholesterolemic mice. Similarly, no influence of spontaneous hypercholesterolemia on charac-
teristic aneurysmal histopathology was noted in female mice. In confirmatory experiments, induced
hypercholesterolemia also exerted no appreciable effect on AAA progression and histopathologies.
Conclusion: This study demonstrated no recognizable impact of hypercholesterolemia on elastase-
induced experimental AAA progression in both spontaneous and induced hypercholesterolemia
mouse models. These results add further uncertainty to the controversy surrounding the efficacy of
statin therapy in clinical AAA disease.
Keywords: abdominal aortic aneurysm; hypercholesterolemia; high-fat diet; PCSK9; leukocytes;
angiogenesis
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1. Introduction
Abdominal aortic aneurysms (AAAs) are a life-threatening consequence of aging.
Development of AAA disease is predicated on both inherited and acquired predisposi-
tions (www.cdc.gov/heartdisease/aortic_aneurysm.htm, accessed on 20 September 2021).
Epidemiological studies associate hypercholesterolemia with modest AAA disease risk
(odds ratio 1.31–1.44) relative to those posed by cigarette smoking (2.61–12.13, depending
on intensity and duration), male sex (5.71) and advancing age (1.67–28.37) [1,2]. More
recently, elevated lipid variant genetic risk scores have also been associated with AAA
disease (odds ratio 1.40–1.47) [3]. However, interventional trials of serum lipid-lowering
pharmaceutical strategies to limit progression of clinical and experimental AAAs using
β-hydroxy β-methylglutaryl-CoA reductase inhibitors, aka statins, have produced incon-
sistent results [4–13].
More than 60% of mice with genetic and diet-induced hypercholesterolemia develop
AAAs following subcutaneous angiotensin (Ang) II administration [13–16]. Given the
dependency on exogenous Ang II for aneurysm formation in these models, however, the
influence of hypercholesterolemia as an independent risk factor for experimental AAA
progression has been difficult to assess.
In the present study, the influence of spontaneous and induced hypercholesterolemia
on experimental AAA progression was evaluated in an alternative model, with aneurysms
created by transient intra-aortic infusion of porcine pancreatic elastase (PPE). This model
demonstrates progressive aneurysmal aortic enlargement and multiple histopathologic
features characteristic of clinical aneurysm disease without a prerequisite for hypercholes-
terolemia at AAA initiation. This enabled an independent assessment of the influence
hypercholesterolemia on experimental AAA pathogenesis.
2. Materials and Methods
2.1. Induction of Hypercholesterolemia and Definition of Model-Specific Control Mice
Two complementary mouse hypercholesterolemic modeling systems were employed.
ApoE−/− mice on a C57BL/6J genetic background served a spontaneous hypercholes-
terolemia model, with wild type (WT) C57BL/6J mice serving as normocholesterolemic
controls. In a second model, male WT C57BL/6J mice were infected with proprotein conver-
tase subtilisin/kexin type 9 (PCSK9) D377Y adeno-associated virus (AAV) via i.p. (intraperi-
toneal) injection. This AAV construct encodes a gain-of-function (GoF) mutation to PSCK9
to degrade low-density lipoprotein (LDL) receptor function in infected cells. These mice
were subsequently fed high-fat-diet (HFD) chow (42% calories from fat, TD.88137, ENVIGO,
Indianapolis, IN, USA) exclusively for two weeks prior to AAA initiation (PCSK9+HFD
group) [17]. As normocholesterolemic controls for PCSK9+HFD mice, WT mice were either in-
fected with PCSK9 AAV and fed a normal laboratory diet or injected with phosphate-buffered
saline (PBS) alone and fed the HFD. Serum cholesterol concentrations were measured using
PRIMA cholesterol test strips (Prima Lab SA, Mano, Switzerland).
All mice were obtained from The Jackson Laboratory (Bar Harbor, ME), and used at the
age of 8–9 weeks for experiments. Animal use, care, and experimental procedures in this
study were approved by the Stanford Administrative Panel on Animal Care (APLC protocol
#11131) and conducted in compliance with the Stanford Laboratory Animal Care Guidelines.
2.2. Experimental AAA Creation
Aneurysms were created by transient intra-infrarenal aortic infusion of PPE as detailed
previously [13,14]. Briefly, the mice were anesthetized with isoflurane inhalation, and all
surgical procedures were performed under sterile conditions. The infrarenal aorta was
exposed and controlled via midline laparotomy, with ligation of all visualized branch
arteries. The aortic bifurcation was cannulated with BTPU-010 polyurethane tube to allow
the infusion of 30 µL PPE (1.5 U/mL in saline) over 5 min. In 8–10-week-old WT C57BL/6J
normocholesteroemic male mice, this infusion procedure is sufficient for producing AAAs
with an average maximal luminal aortic diameter of 1.2–1.3 mm within 14 days following
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PPE infusion. The aortotomy was closed with 10–0 nylon suture. Following closure of the
laparotomy, mice were housed in individual cages for postsurgical recovery and aneurysm
monitoring. The surgical mortality in this model ranges from 10 to 15%.
2.3. Imaging AAA Formation and Progression
Aortic aneurysmal enlargement was monitored by serial transabdominal high fre-
quency ultrasound (40 MHz, Vevo 2100, VisualSonics, Toronto, ON, Canada) assessments
following postsurgical recovery [13]. Measurements were performed one day prior to
(baseline, day 0), and 3, 7, and 14 days following, PPE infusion by investigators blinded
to experiment group assignment. In each ultrasound examination, the maximal internal
aortic diameter within the PPE-infused infrarenal segment was measured from transverse
aortic images stored within the Vevo@Imaging System software. The presence of AAA was
defined as a ≥ 50% increase in pre-infusion aortic diameter. Although definitions vary as to
what degree of aortic diameter constitutes an “aneurysm”, in this model, a ≥ 50% increase
compared to age-adjusted population norms is consistent with the clinical definition of
AAA disease. In PBS-infused control mice, the magnitude of infusion-induced mechanical
distension of the infrarenal segment in the absence of aneurysm formation was reflected by
average diameter enlargements of 21%, 18% and 15% on days 3, 7 and 14, respectively.
2.4. Histological Analyses
Mice were sacrificed 14 days after PPE infusion. Aortae were harvested, embedded
in optimal cutting temperature compound media, sectioned (6 µm), and acetone-fixed.
Medial elastin was assessed using Elastic Van Gieson (EVG) stain [18]. A 2- or 3-step
standard immunoperoxidase procedure for immunohistochemistry was used to identify
medial smooth muscle cells (SMC, SMC α-actin), mural neoangiogenesis (CD31) and
aortic leukocyte accumulation (macrophages, CD4 and CD8 T cells, and B cells) using
subset-specific monoclonal antibodies (mAbs). Primary and secondary antibodies, other
immunostaining reagents, and their working conditions are provided in Table 1. Based on
staining patterns of EVG, SMC α-actin mAb, or CD68 mAb, medial elastin degradation,
SMC depletion, and macrophage accumulation were scored on a scale of I (mild) to IV
(severe) (Figure 1) [19]. Mural neoangiogenesis and other leukocytes were quantified as
CD31-positive vessels or subset mAb-positive cells per aortic cross-section (ACS).
Table 1. Sources and working conditions for immunohistochemical reagents.
Reagent Manufacture Catalog # Clone # Working Solution(µg/mL)
Incubation Time at Room
Temperature (Minutes)
Rat anti-mouse-B220 mAb Biolegend 103201 RA3-6B2 2.5 60
Rat-anti-mouse CD4 mAb Biolegend 100402 GK1.5 2.5 60
Rat anti-mouse CD8 mAb Biolegend 100702 53–6.7 2.5 60
Rat anti-mouse CD68 mAb Biolegend 137002 FA-11 2.5 60
Biotin-mouse anti-mouse
SMC α actin mAb
Thermo Fisher
















Laboratories, Inc. SK-4200 N/A N/A 10–20
mAb: monoclonal antibody.
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Figure 1. Representative histological images demonstrating the grading system used to categorize medial elastin and SMC 
destruction and macrophage accumulation. Aneurysmal aortas from porcine pancreatic elastase-infused mice were 
stained with Elastic Van Gieson (EVG) stain for medial elastin, SMC α-actin antibody for SMCs and CD68 antibody for 
macrophages, respectively. Medial elastolysis and SMCs as well as macrophage densities were graded as I (mild) to IV 
(severe). Grade I: elastin degradation, SMC loss, or aggregate macrophage accumulation involves <25% of aortic circum-
Figure 1. Representative histological images demonstrating the grading system used to categorize medial elastin and SMC
destruction and macrophage accumulation. Aneurysmal aortas from porcine pancreatic elastase-infused mice were stained
with Elastic Van Gieson (EVG) stain for medial elastin, SMC α-actin antibody for SMCs and CD68 antibody for macrophages,
respectively. Medial elastolysis and SMCs as well as macrophage densities were graded as I (mild) to IV (severe). Grade I: elastin
degradation, SMC loss, or aggregate macrophage accumulation involves <25% of aortic circumference (AC) or diffuse
mac ophage infiltr tio . Grade II: elastin degradation, SMC loss, or ag regate acrophage accumulation involves ≥25%
but <50% of AC. Grade III: elastin degradation, SMC loss, or aggregate macrophage accumulation involves ≥50% but <75% of
AC. Grade IV: elastin degradation, SMC loss, or aggregate macrophage accumulation involves ≥75% of AC.
2.5. Statistical Analyses
All statistical analyses were performed using GraphPad Prism (Ver 8.0.1 GraphPad
Prism Software, Inc., San Diego, CA, USA). The Shapiro–Wilk normality test was used to
determine whether individual datasets were normally distributed. All normally distributed
data were presented as mean and 95% confidence interval (CI), and either Student’s t-test
or two-way repeated measures ANOVA, followed by the Newman–Keuls post hoc test,
were used to determine the significance between groups. All non-normally distributed
data are presented as median and 95% CI, and nonparametric Mann–Whitney test was
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used to determine differences between two groups. In all statistical analyses, p<0.05 was
considered significant.
3. Result
3.1. No Effect of Spontaneous Hypercholesterolemia on Experimental AAA Diameter
Both male (mean and 95% CI: 737, 695–779 mg/dL) and female (662, 580–744 mg/dL)
ApoE−/− mice achieved significantly higher serum cholesterol concentrations than those
measured in age-matched WT male (171, 147–195 mg/dL) and female (154, 129–178 mg/dL)
mice (Figure 2A).
Following PPE infusion, both male WT and ApoE−/− mice experienced significant
infrarenal aortic enlargement from day 3 through day 14 (Figure 2B,C). The rate of en-
largement did not differ between the two groups at any time following AAA induction.
Aneurysm diameters were 1.4 (1.18–1.29) (mean and 95% CI) and 1.24 (1.15–1.33) mm for
WT and ApoE−/− mice, respectively, 14 days following PPE infusion. Similar progression
was noted in female mice (Figure 2D). Regardless of sex or strain, all mice developed AAAs
as defined by a more than 50% increase in aortic diameter over baseline measurements.
Additionally, female mice experienced less aortic diameter enlargement than strain-
matched male mice following PPE infusion, regardless of ApoE status (Figure 2E,F). These
data indicate that spontaneous hypercholesteremia due to ApoE deficiency had no impact
on sex-dependent differences in experimental AAA progression. Taken together, these
results indicate that spontaneous hypercholesterolemia in mice deficient for ApoE exerts
minimal influence on development and progression of PPE-induced experimental AAAs.
3.2. No Effect of Spontaneous Hypercholesterolemia on AAA Histopathology
The potential influence of hypercholesterolemia on characteristic experimental AAA
histopathology was assessed by comparison of aortic medial elastin degradation, SMC
depletion, mural leukocye accumulation, and neovessel formation between groups.
Elastin degradation was scored as 3.5 (1.0–4.0) (median and 95% CI) in male normocholes-
terolemic WT mice, involving 50 to 75% of the aortic circumference (AC) (Figures 3 and 4A).
This degree of elastolysis was not significantly different from that noted in hypercholesteremic
ApoE−/− male mice (3.0, 2.0–4.0). SMC depletion was graded as 4.0 (3.0–4.0) and 4.0 (2.0–4.0)
for male normo- and hypercholesterolemic mice, respectively, involving more than 75% of
AC (Figures 3 and 4B). Again, no difference was noted between groups.
Macrophages were the predominant leukocyte subset present in aneurysmal lesions
from both normo- and hyper-cholesterolemic male mice (Figures 3 and 4). The median
score for macrophage accumulation was 3.5 (2.0–4.0) in male normocholesterolemic mice,
indicating macrophage accumulation in 50–75% of AC. Such accumulation was similar to
those noted in male hypercholesterolemic mice (4.0, 3.0–4.0; Figures 3 and 4C). Normoc-
holesterolemic male mouse aortae demonstrated more aortic mural CD4 (mean and 95%
CI: 140, 94–185 cells/ACS) and CD8 (74, 23–127 cells/ACS) positive T cells as compared
to hypercholesterolemic controls (113, 73–152 cells/ACS for CD4 T cells and 58, 36–79
cells/ACS for CD8 T cells) (Figures 3 and 4D,E). B cells accumulated at the same magnitude
in both male normo- (media and 95% CI: 71, 36–226) and hypercholesterolemic (72, 23–107)
mice (Figures 3 and 4F). Overall, no significant differences in individual leukocyte subsets
were noted between normo- and hyper-cholesterolemic male mice.
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Figure 3. Representative AAA histology in male normocholesterolemic WT and spontaneous hyperc-
holesterolemic ApoE−/− mice. Fourteen days following elastase infusion, aortae were harvested,
embedded in optimal cutting temperature compound, sectioned (6–8 µm), and fixed with acetone.
Medial elastin was stained with Elastic Van Gieson (EVG) staining. Smooth muscle cells (SMC),
macrophages, CD4-positive T cells, and neovessels were stained using monoclonal antibodies to
SMC α-actin, CD68, CD4, and CD31. Lum: lumen. Int: Intima. Med: Media. Adv: Adventitia. Scale
bar: 200 µm.
Biomolecules 2021, 11, 1434 8 of 15
Biomolecules 2021, 11, x FOR PEER REVIEW 8 of 15 
 
embedded in optimal cutting temperature compound, sectioned (6–8 μm), and fixed with acetone. 
Medial elastin was stained with Elastic Van Gieson (EVG) staining. Smooth muscle cells (SMC), 
macrophages, CD4-positive T cells, and neovessels were stained using monoclonal antibodies to 
SMC α-actin, CD68, CD4, and CD31. Lum: lumen. Int: Intima. Med: Media. Adv: Adventitia. Scale 
bar: 200 μm. 
 
Figure 4. Quantification of AAA histopathological features between elastase-infused male normocholesterolemic WT and 
hypercholsterolemic ApoE−/− mice (n = 8 mice/group). (A–C) Median and 95% confidence interval (CI) of the scores for 
medial elastin (A) and smooth muscle cell (SMC) (B) destruction as well as CD68-positive macrophage accumulation. 
Score I to IV represent mild to severe destruction. (D,E) Mean and 95% CI for CD4+ T cells (E) and CD8+ T cells (F) per 
aortic cross-section (ACS). (F) Median and 95% CI for B220-positive B cells per ACS. (G) Mean and 95% CI of CD31-
positive neovessels per ACS. Nonparametric Mann–Whitney test (A–C,F) or Student’s t-test (D,E,G) indicated no signifi-
cance difference between two groups. 
Macrophages were the predominant leukocyte subset present in aneurysmal lesions 
from both normo- and hyper-cholesterolemic male mice (Figures 3 and 4). The median 
score for macrophage accumulation was 3.5 (2.0–4.0) in male normocholesterolemic mice, 
indicating macrophage accumulation in 50–75% of AC. Such accumulation was similar to 
those noted in male hypercholesterolemic mice (4.0, 3.0–4.0; Figures 3 and 4C). Normo-
cholesterolemic male mouse aortae demonstrated more aortic mural CD4 (mean and 95% 
CI: 140, 94–185 cells/ACS) and CD8 (74, 23–127 cells/ACS) positive T cells as compared to 
hypercholesterolemic controls (113, 73–152 cells/ACS for CD4 T cells and 58, 36–79 
cells/ACS for CD8 T cells) (Figures 3 and 4D,E). B cells accumulated at the same magni-
tude in both male normo- (media and 95% CI: 71, 36–226) and hypercholesterolemic (72, 
Figure 4. Quantification of AAA histopathological features between elastase-infused male normocholesterolemic WT and
hypercholsterolemic ApoE−/− mice (n = 8 mice/group). (A–C) Median and 95% confidence interval (CI) of the scores
for medial elastin (A) and smooth muscle cell (SMC) (B) destruction as well as CD68-positive macrophage accumulation.
Score I to IV represe t mild to severe destruction. D,E) Mean and 95% CI for CD4+ T cells (E) and CD8+ T cells (F) per
aortic cr ss-section (ACS). (F) Median and 95% CI for B220-positive B cells per ACS. (G) M an and 95% CI of CD31-positive
neovessels per ACS. Nonparametric Mann–Whitney test (A–C,F) or Student’s t-test (D,E,G) indicated no significance
difference between two groups.
Mural neoangiogenesis is another hallmark pathologic feature of aneurysmal aortic de-
generation. Neovessel density, as enumerated by CD31-positive vessels, was indistinguish-
able between normo- (mean and 95% CI: 55, 39–62 vessels/ACS) and hypercholesterolemic
(52, 29–70 vessels/ACS) mouse a rtae (Figures 3 and 4G).
Similar histological analyses were also performed for aorti sections from PPE-infused
female normo- and l l i i . Median scores for elastin and SMC de-
struction were identical, scoring as 4.0 with 95% CI of 1.0–4.0 (EVG) and 2.0–4.0 (SMC)
(Figure 5A,B). While more macrophages, CD4+ T cells and CD8+ T cells were not in
- as compared to normocholesterolemic female mouse AAAs, these differences were
not statistically significant 5C–E). Likewise, the extent of B cell accumulation a d
aortic mural angiogenesis were indistinguishable between groups (Figure 5F,G).
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Figure 5. Quantification of AAA histopathological features in elastase-infused normocholesterolemic WT and hypercholes-
terolemic ApoE−/− female mice (n = 7 and 8 mice in WT and ApoE−/− mouse groups, respectively). (A–C): Media and
95% confidence interval (CI) of the scores for medial elastin (A) and smooth muscle cell (SMC) (B) destruction as well
as CD68-positive macrophage accumulation (C). Scores I to IV represent mild to severe destruction. (D): Mean and 95%
I for CD4+ T cells (E) per aortic cross-section (ACS). (E,F): Media and 95% CI for CD8+ T ells (E) B220+ B cells (F) per
ACS. (G): Mean and 95% CI of CD31+ ne vessels per ACS. Nonp rametric Mann–Whitney test (A–C,E,F) or Student’s t-test
(D,G) indicated no significance difference between two groups.
These results indicate that spontaneous hypercholesterolemia exerted no measurable
effect on characteristic experimental AAA histopathol gy induced by intra-aortic transient
PPE infusion.
3.3. No Differences in Aneurysmal Progresssion and Histopathologies Noted between
Normocholesterolemia and “Acquired” Hypercholesterolemia
To validate and generalize these findings beyond those observed in spontaneous hyper-
cholesterolemia, an “acquired” mouse hypercholesterolemia model was developed and em-
ployed. In this model, male WT C57BL/6J mice were intraperitoneally injected with an AAV
encoding GoF mutation of PCSK9 and subsequently fed a HFD for 2 weeks (PSCK9+HFD).
These interventions resulted in significant elevation of serum cholesterol concentrations in
PCSK9+HFD mice (mean and 95% CI: 854, 749–959 mg/dL) as compared to mice inoculated
with PCSK9 AAV and fed a normal laboratory diet alone (177, 159–196 mg/dL) or injected
with PBS alone and fed a HFD (196, 146–246). This confirmed the successful induction of
hypercholesterolemia in this model (Figure 6A).
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Figure 6. Influence of induced hypercholesterolemia on aneurysm enlargement and aortic pathologies. Male WT mice at
age of 8 weeks were injected with phosphate-buffered saline (PBS) and immediately fed a high-fat diet (HFD), infected with
PCSK9/AAV and immediately fed either normal laboratory chow (PCSK9) or HFD (PCSK9+HFD). Two weeks thereafter,
mice underwent transient intra-aortic PPE infusion for AAA induction and continued on their pre-assigned diets. (A) Mean
and 95% confidence interval (CI) of serum cholesterol concentrations measured via cholesterol strips (n = 7 mice in PCSK9
and HFD groups and 8 mice in PCSK9+HFD group). (B) Mean and 95% CI of infrarenal aortic luminal diameters prior to
and indicated days after, PPE infusion imaged via ultrasonography. (C–E) Median and 95% CI for histological scores for
elastin degradation (C), smooth muscle cell (SMC) depletion (D) and macrophage (E). Medial elastin degradation, SMC
depletion and macrophage accumulation were graded as I (mild) to IV (severe). (F–I) Mean and 95% CI of CD4+ T cells
(F), CD8+ T cells (G), B220+ B cells (H) and CD31+ neovessels (I) per aortic cross-section (ACS). Student’s t-test, ** p < 0.01
compared to PCSK9 and HFD groups (A). Two-way ANOVA followed by Newman–Keuls post hoc test, no difference was
noted between the groups (B). Nonparametric Mann–Whitney test indicated no significant difference between two groups,
test (B–I).
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All mice experienced equal time-dependent, progressive aortic enlargement following
PPE infusion regardless of GoF PCSK9 or dietary category (Figure 6B) in these experiments.
On day 14, aortic diameters were 1.21 (1.14–1.27) (mean and 95% CI), 1.27 (1.19–1.34) and
1.24 (1.19, 1,29) mm in HFD, PCSK9 and PCSK9+HFD mice, respectively. AAAs developed
in all mice within 7 days following PPE infusion.
No significant differences were found for medial elastin and SMC destruction among
the groups, with median scores of 3.0 for elastin degradation and 3.5 to 4.0 for SMC deple-
tion (Figure 6C,D). Induced hypercholesterolemia also did not affect mural macrophage
accumulation with all groups scoring 3 with a 95% CI of 1.0 and 4.0, indicating dense focal
macrophage accumulation involving 50 to 75% of the aortic circumference (Figure 6E).
Mural accumulation of CD4+ T cells, CD8+ T cells, and B cells, as evaluated by positively
stained cells/ACS, were not significant for any leukocyte subsets (Figure 6F–H). Similarly,
neovessel density, as quantified by CD31+ vessels per ACS, was indistinguishable among
three groups (Figure 6I).
Collectively, these results support the conclusion that hypercholesterolemia, whether
spontaneous or HFD-induced, does not influence progression of experimental AAAs
induced via intra-aortic PPE infusion.
4. Discussion
In the PPE intra-aortic infusion model, the presence of hypercholesterolemia exerted
no significant effect on the prevalence, progression, or histopathological features of ex-
perimental AAAs. These findings support those of Steinmetz and associates, who found
no effect of ApoE deficiency on experimental AAAs created in a similar modeling sys-
tem [20]. In alternative AAA modeling systems, however, hypercholesterolemic ApoE−/−
mice reportedly experienced more significant experimental aneurysm progression [21],
challenging the translational relevance of findings from both models. However, significant
differences exist in the mechanisms and consequences of AAA induction between models.
In the latter case, following AAA induction via abluminal application of calcium chlo-
ride the ApoE−/− mice were noted to have more pronounced aortic medial calcification,
creating the possibility that calcification, rather than hypercholesterolemia per se, may
accelerate experimental AAA progression [22–26].
Prior studies evaluating the ability of lipid-lowering drugs to suppress experimental
aneurysms in distinct AAA modeling systems have yielded inconsistent results. For in-
stance, simvastatin, across a large dose range (2–60 mg/kg), inhibited the progression of
experimental AAAs created by intra-aortic elastase infusion, subcutaneous Ang II infusion,
or abluminal peri-aortic calcium chloride application without apparent influence on serum
cholesterol concentrations [10,11,20,27–29]. Pitavastatin mitigated experimental AAAs
induced by either elastase infusion in normocholesterolemic rats, or Ang II infusion in
hypercholesterolemic mice, in conjunction with enhanced intracellular drug concentrations
resulting from nanoparticle-enhanced delivery, also without apparent effect on serum
cholesterol concentrations [30,31]. Atorvastatin also suppressed experimental AAAs at
high (20 mg/kg) but not intermediate (10 mg/kg) or low (1 mg/kg) doses, also without
modulating circulating cholesterol concentrations. However, fluvastatin or rosuvastatin
administration, although effective in attenuating expression of certain aortic inflammatory
mediators, did not influence the incidence, enlargement, or rupture of experimental AAAs.
From these studies, it is apparent that when present, statin-mediated experimental AAA
suppression may result from off-target pharmacological effects unrelated to cholesterol-
lowering effect or cholesterol metabolism. Regardless of the efficacy of specific statins or
the mode of administration, these findings add credence to the conclusion that hyperc-
holesterolemia alone does not promote or accelerate experimental AAA progression.
Ang II and its type 1 receptor mediate AAA pathogenesis in both exogenous Ang
II-dependent and independent models [13,32–34]. In normocholesteroemic mice, min-
imal AAA formation was noted in response to exogenous Ang II administration [35].
Hypercholesterolemia, regardless of the method of induction, significantly enhances the
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AAA-promoting effects of Ang II [15–17,36,37]. Beyond hypercholesterolemia, various
factors also promote AAA formation following exogenous Ang II administration. These in-
clude obesity (as a consequence of long-term HFD) in the absence of hypercholesterolemia,
neutralization of transforming growth factor-β, chemical destabilization of extracellular
matrix protein cross-linking via β-aminopropionitrile monofumarate administration, and
genetic deficiency of nuclear factor erythroid 2-related factor 2 [35,38–42]. Thus, while
clearly capable of promoting experimental AAAs, hypercholesterolemia may not be a
specific, absolute requirement for aneurysm induction and progression in response to
exogenous Ang II.
Hypercholesterolemia is recognized as a mild to moderate epidemiologic risk for AAA
disease relative to those posed by either cigarette smoking, male sex, or advanced age [1,2].
Statin therapy also reduces all-cause short- and long-term mortality following surgical
AAA repair [7,43,44]. Controversy continues regarding the influence of statin therapy on
disease progression. This is partly due to lingering uncertainty regarding the value of
the rate of AAA enlargement as a valid clinical endpoint vs. the “harder” endpoints of
surgical repair, rupture, or aneurysm-related death. Statins have shown efficacy in limiting
further AAA enlargement in small cohort prospective studies or meta-analyses combining
cross-sectional, retrospective, and prospective studies without subgroup analyses [4–7].
Almost uniformly, these preliminary reports have not been validated by larger prospective
studies or high-quality subgroup meta-analyses [8,9,45]. The experimental finding that
hypercholesterolemia exerted no independent effect on experimental AAA initiation or
progression adds further perspective to the inconsistent clinical observations regarding
statin therapy and AAA disease progression.
PCSK9 lowers blood LDL cholesterol by binding to the cell surface LDL receptor.
PCSK9 activity may be altered genetically or pharmacologically. In the Million Veterans
Program of the United States Department of Veterans Affairs, a PCSK9 mutation associated
with reduced serum LDL cholesterol levels was also associated with a 28% reduction in risk
for AAA disease. In contrast, an enhanced polygenetic lipid variant risk score increased
AAA risk by 40% or more [3]. In the current GoF mutant PCSK9 experiments, AAV in-
fection alone, with or without a HFD, exerted no recognizable influence on experimental
aneurysm progression or characteristic pro-aneurysmal aortic pathologies. Putative associ-
ations between PCSK9 variants or polygenetic lipid variant risk scores and AAA disease
may be confounded by common risk factors for atherosclerosis and AAAs [46], or alter-
ations in aortic inflammation, stiffness or structural features such as vascular-associated
lymphoid tissues secondary to co-existing atherosclerosis may also link cholesterol to AAA
risk [22–26,47–49]. Further analysis of AAA enlargement rates in patients treated with
PCSK9 inhibitors (Alirocumab and Evolocumab) may provide further understanding of
the role of serum lipid and cholesterol concentrations in clinical AAA disease.
5. Conclusions
These results provide compelling evidence that neither spontaneous nor induced
hypercholesterolemia influences the initiation, enlargement, or characteristic pathologic
progression of elastase-induced experimental AAAs in mice.
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AAA: abdominal aortic aneurysm; AAV: adeno-associated virus; AC: aortic circuference;
ACS: aortic cross-section; Ang: angiotensin; ApoE: apolipoprotein E; CI: confidence interval; EVG:
Elastic Van Gieson; GoF: gain-of-function; HFD: high-fat diet; i.p.: intra-peritoneal; LDL: low-density
lipoprotein; mAb: monoclonal antibody; phosphate-buffered saline: PBS; PCSK9: proprotein conver-
tase subtilisin/kexin type9; PPE: porcine pancreatic elastase; SMC: smooth muscle cell; WT: wild type.
References
1. Lederle, F.A.; Johnson, G.R.; Wilson, S.E.; Chute, E.P.; Hye, R.J.; Makaroun, M.S.; Barone, G.W.; Bandyk, D.; Moneta, G.L.; Makhoul,
R.G. The aneurysm detection and management study screening program: Validation cohort and final results. Aneurysm detection
and management veterans affairs cooperative study investigators. Arch. Intern. Med. 2000, 160, 1425–1430. [CrossRef] [PubMed]
2. Kent, K.C.; Zwolak, R.M.; Egorova, N.N.; Riles, T.S.; Manganaro, A.; Moskowitz, A.; Gelijns, A.C.; Greco, G. Analysis of risk
factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J. Vasc. Surg. 2010, 52, 539–548. [CrossRef]
[PubMed]
3. Klarin, D.; Damrauer, S.M.; Cho, K.; Sun, Y.V.; Teslovich, T.M.; Honerlaw, J.; Gagnon, D.R.; DuVall, S.L.; Li, J.; Peloso, G.M.; et al.
Genetics of blood lipids among ~300,000 multi-ethnic participants of the million veteran program. Nat. Genet. 2018, 50, 1514–1523.
[CrossRef] [PubMed]
4. Pan, Z.; Cui, H.; Wu, N.; Zhang, H. Effect of Statin Therapy on Abdominal Aortic Aneurysm Growth Rate and Mortality: A
Systematic Review and Meta-analysis. Ann. Vasc. Surg. 2020, 67, 503–510. [CrossRef]
5. Schouten, O.; Van Laanen, J.; Boersma, E.; Vidakovic, R.; Feringa, H.; Dunkelgrün, M.; Bax, J.; Koning, J.; Van Urk, H.; Poldermans,
D. Statins are Associated with a Reduced Infrarenal Abdominal Aortic Aneurysm Growth. Eur. J. Vasc. Endovasc. Surg. 2006, 32,
21–26. [CrossRef]
6. Takagi, H.; Yamamoto, H.; Iwata, K.; Goto, S.; Umemoto, T. Effects of Statin Therapy on Abdominal Aortic Aneurysm Growth:
A Meta-analysis and Meta-regression of Observational Comparative Studies. Eur. J. Vasc. Endovasc. Surg. 2012, 44, 287–292.
[CrossRef]
7. Salata, K.; Syed, M.; Hussain, M.A.; de Mestral, C.; Greco, E.; Mamdani, M.; Tu, J.V.; Forbes, T.L.; Bhatt, D.L.; Verma, S.; et al.
Statins reduce abdominal aortic aneurysm growth, rupture, and perioperative mortality: A systematic review and meta-analysis.
J. Am. Heart Assoc. 2018, 7, e008657. [CrossRef]
8. Ferguson, C.D.; Clancy, P.; Bourke, B.; Walker, P.J.; Dear, A.; Buckenham, T.; Norman, P.; Golledge, J. Association of statin
prescription with small abdominal aortic aneurysm progression. Am. Heart J. 2010, 159, 307–313. [CrossRef]
9. Twine, C.; Williams, I.M. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. J.
Br. Surg. 2010, 98, 346–353. [CrossRef]
10. Zhang, Y.; Naggar, J.C.; Welzig, C.M.; Beasley, D.; Moulton, K.S.; Park, H.J.; Galper, J.B. Simvastatin inhibits angiotensin ii-induced
abdominal aortic aneurysm formation in apolipoprotein e-knockout mice: Possible role of erk. Arter. Thromb. Vasc. Biol. 2009, 29,
1764–1771. [CrossRef]
11. Golledge, J.; Cullen, B.; Moran, C.; Rush, C. Efficacy of Simvastatin in Reducing Aortic Dilatation in Mouse Models of Abdominal
Aortic Aneurysm. Cardiovasc. Drugs Ther. 2010, 24, 373–378. [CrossRef]
12. Takahashi, K.; Matsumoto, Y.; Doe, Z.; Kanazawa, M.; Satoh, K.; Shimizu, T.; Sato, A.; Fukumoto, Y.; Shimokawa, H. Combination
therapy with atorvastatin and amlodipine suppresses angiotensin ii-induced aortic aneurysm formation. PLoS ONE 2013, 8, e72558.
[CrossRef] [PubMed]
13. Iida, Y.; Xu, B.; Schultz, G.M.; Chow, V.; White, J.J.; Sulaimon, S.; Hezi-Yamit, A.; Peterson, S.R.; Dalman, R.L. Efficacy and Mechanism
of Angiotensin II Receptor Blocker Treatment in Experimental Abdominal Aortic Aneurysms. PLoS ONE 2012, 7, e49642. [CrossRef]
[PubMed]
14. Iida, Y.; Xu, B.; Xuan, H.; Glover, K.J.; Tanaka, H.; Hu, X.; Fujimura, N.; Wang, W.; Schultz, J.R.; Turner, C.R.; et al. Peptide
Inhibitor of CXCL4–CCL5 Heterodimer Formation, MKEY, Inhibits Experimental Aortic Aneurysm Initiation and Progression.
Arter. Thromb. Vasc. Biol. 2013, 33, 718–726. [CrossRef] [PubMed]
15. Daugherty, A.; Cassis, L. Chronic Angiotensin II Infusion Promotes Atherogenesis in Low Density Lipoprotein Receptor -/- Mice.
Ann. N. Y. Acad. Sci. 1999, 892, 108–118. [CrossRef]
Biomolecules 2021, 11, 1434 14 of 15
16. Daugherty, A.; Manning, M.W.; Cassis, L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein
E–deficient mice. J. Clin. Investig. 2000, 105, 1605–1612. [CrossRef]
17. Lu, H.; Howatt, D.A.; Balakrishnan, A.; Graham, M.J.; Mullick, A.E.; Daugherty, A. Hypercholesterolemia Induced by a PCSK9
Gain-of-Function Mutation Augments Angiotensin II–Induced Abdominal Aortic Aneurysms in C57BL/6 Mice—Brief Report.
Arter. Thromb. Vasc. Biol. 2016, 36, 1753–1757. [CrossRef]
18. Pyo, R.; Lee, J.K.; Shipley, J.M.; Curci, J.A.; Mao, D.; Ziporin, S.J.; Ennis, T.L.; Shapiro, S.D.; Senior, R.M.; Thompson, R.W.
Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic
aneurysms. J. Clin. Investig. 2000, 105, 1641–1649. [CrossRef]
19. Fujimura, N.; Xiong, J.; Kettler, E.; Xuan, H.; Glover, K.J.; Mell, M.W.; Xu, B.; Dalman, R.L. Metformin treatment status and
abdominal aortic aneurysm disease progression. J. Vasc. Surg. 2016, 64, 46–54. [CrossRef]
20. Steinmetz, E.F.; Buckley, C.; Shames, M.L.; Ennis, T.L.; Vanvickle-Chavez, S.J.; Mao, D.; Goeddel, L.A.; Hawkins, C.J.; Thompson,
R.W. Treatment With Simvastatin Suppresses the Development of Experimental Abdominal Aortic Aneurysms in Normal and
Hypercholesterolemic Mice. Ann. Surg. 2005, 241, 92–101. [CrossRef]
21. Wang, Y.; Krishna, S.M.; Moxon, J.; Dinh, T.N.; Jose, R.J.; Yu, H.; Golledge, J. Influence of apolipoprotein E, age and aortic site on
calcium phosphate induced abdominal aortic aneurysm in mice. Atherosclerosis 2014, 235, 204–212. [CrossRef] [PubMed]
22. Niederhoffer, N.; Lartaud-Idjouadiene, I.; Giummelly, P.; Duvivier, C.; Peslin, R.; Atkinson, J. Calcification of medial elastic fibers
and aortic elasticity. Hypertension 1997, 29, 999–1006. [CrossRef] [PubMed]
23. Ng, K.; Hildreth, C.M.; Phillips, J.K.; Avolio, A.P. Aortic stiffness is associated with vascular calcification and remodeling in a
chronic kidney disease rat model. Am. J. Physiol. Physiol. 2011, 300, F1431–F1436. [CrossRef] [PubMed]
24. Bhat, O.M.; Yuan, X.; Cain, C.; Salloum, F.; Li, P. Medial calcification in the arterial wall of smooth muscle cell-specific Smpd1
transgenic mice: A ceramide-mediated vasculopathy. J. Cell. Mol. Med. 2019, 24, 539–553. [CrossRef] [PubMed]
25. Wagenhäuser, M.U.; Schellinger, I.N.; Yoshino, T.; Toyama, K.; Kayama, Y.; Deng, A.; Guenther, S.P.; Petzold, A.; Mulorz, J.;
Mulorz, P.; et al. Chronic nicotine exposure induces murine aortic remodeling and stiffness segmentation-implications for
abdominal aortic aneurysm susceptibility. Front. Physiol. 2018, 9, 1459. [CrossRef] [PubMed]
26. Raaz, U.; Zöllner, A.M.; Schellinger, I.N.; Toh, R.; Nakagami, F.; Brandt, M.; Emrich, F.C.; Kayama, Y.; Eken, S.; Adam, M.; et al.
Segmental Aortic Stiffening Contributes to Experimental Abdominal Aortic Aneurysm Development. Circulation 2015, 131,
1783–1795. [CrossRef] [PubMed]
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